Company: STAA
Filing Date: 2025-12-11
Form Type: DFAN14A
Source: 0001213900-25-120777
Chunk: 23

Company: STAAR SURGICAL CO
Filing Date: 2025-12-11
Form: DFAN14A
Chunk 23
---
� Despite these positive developments, the Board continues to rely on a fairness opinion that is more than four months old ▪ Given such evident progress and the prospect of material improvement to STAAR’s business fundamentals, we see no reason why stockholders should accept a sale of the Company now, especially at a revised offer price that remains near multi - year lows 1. Source: STAAR proxy statement on Form DEFM14A, filed with the SEC on September 16, 2025.

CONFIDENTIAL © All rights reserved. Two Seas Capital LP SUPPLEMENTAL INVESTOR PRESENTATION APPENDIX A: Trading Multiples of Comparable Medical Technology Companies 05

Broadwood Partners, L.P. Trading Multiples of Comparable Medical Technology Companies 35 Source: FactSet. Data as of December 8, 2025. 1. Based on management’s revised projections as disclosed in STAAR proxy statement on Form DEFM14A, filed with the SEC on Septem ber 16, 2025 at 61. Implied Value of STAAR at EV / Revenue Multiple EV / Revenue Multiple CY 2027E CY 2026E CY 2025E CY 2027E CY 2026E CY 2025E Enterprise Value ($M) Company Name $25.90 $25.36 $23.08 3.6x 3.9x 4.2x $43,178 Alcon AG $25.15 $26.58 $25.97 3.5x 4.1x 4.8x $3,632 Alphatec Holdings, Inc. $19.78 $20.38 $19.32 2.7x 3.0x 3.4x $1,801 AtriCure , Inc. $34.87 $37.14 $36.03 5.1x 6.0x 6.9x $1,540 Axogen , Inc. $30.63 $31.52 $29.84 4.4x 5.0x 5.6x $25,987 DexCom, Inc. $46.36 $53.02 $55.20 6.9x 8.7x 10.9x $2,299 Establishment Labs Holdings, Inc. $51.76 $59.51 $61.55 7.8x 9.9x 12.3x $6,